Citations (196)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Thomas J Dennison, Julian C Smith, Raj K Badhan & Afzal R Mohammed. (2017) Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Design, Development and Therapy 11, pages 811-826.
Read now
Read now
Sara K. Quinney, Tara Benjamin, Xiaomei Zheng & Avinash S. Patil. (2017) Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism. Fetal and Pediatric Pathology 36:5, pages 400-411.
Read now
Read now
Nuggehally R. Srinivas. (2016) Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Development and Industrial Pharmacy 42:6, pages 945-957.
Read now
Read now
Nuggehally R. Srinivas & Muzeeb Syed. (2016) Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application. Journal of Pain & Palliative Care Pharmacotherapy 30:1, pages 13-24.
Read now
Read now
C. Desbans, C. Hilgendorf, M. Lutz, P. Bachellier, T. Zacharias, J. C. Weber, H. Dolgos, L. Richert & A.-L. Ungell. (2014) Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors. Xenobiotica 44:1, pages 17-27.
Read now
Read now
Kotaro Ogawa, Motohiro Kato, Takao Houjo & Masaki Ishigai. (2013) A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. Xenobiotica 43:5, pages 468-478.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Guillaume Baneyx, Yumi Fukushima & Neil Parrott. (2012) Use Of Physiologically Based Pharmacokinetic Modeling For Assessment Of Drug–Drug Interactions. Future Medicinal Chemistry 4:5, pages 681-693.
Read now
Read now
Hannah M Jones, Maurice Dickins, Kuresh Youdim, James R Gosset, Neil J Attkins, Tanya L Hay, Ian K Gurrell, Y Raj Logan, Peter J Bungay, Barry C Jones & Iain B Gardner. (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:1, pages 94-106.
Read now
Read now
Helen E. Cubitt, Karen R. Yeo, Eleanor M. Howgate, Amin Rostami-Hodjegan & Zoe E. Barter. (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:8, pages 623-638.
Read now
Read now
Karen Rowland Yeo, Mohsen Aarabi, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Review of Clinical Pharmacology 4:2, pages 261-274.
Read now
Read now
Thierry Lavé, Kathryn Chapman, Paul Goldsmith & Malcolm Rowland. (2009) Human clearance prediction: shifting the paradigm. Expert Opinion on Drug Metabolism & Toxicology 5:9, pages 1039-1048.
Read now
Read now
Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, Italo Poggesi & Jean-Baptiste Watelet. (2009) Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 41:3, pages 391-407.
Read now
Read now
C. Emoto, N. Murayama, A. Rostami-Hodjegan & H. Yamazaki. (2009) Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. Xenobiotica 39:3, pages 227-235.
Read now
Read now
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker & Amin Rostami-Hodjegan. (2009) The Simcyp® Population-based ADME Simulator. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 211-223.
Read now
Read now
U. Fagerholm. (2009) Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica 39:1, pages 57-71.
Read now
Read now
Olavi Pelkonen, Jaime Kapitulnik, Ursula Gundert-Remy, AlanR. Boobis & Armel Stockis. (2008) Local Kinetics and Dynamics of Xenobiotics. Critical Reviews in Toxicology 38:8, pages 697-720.
Read now
Read now
H. J. Einolf. (2007) Comparison of different approaches to predict metabolic drug–drug interactions. Xenobiotica 37:10-11, pages 1257-1294.
Read now
Read now
T. Lavé, N. Parrott, H. P. Grimm, A. Fleury & M. Reddy. (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:10-11, pages 1295-1310.
Read now
Read now
Jan L Wahlstrom, Dan A Rock, J Greg Slatter & Larry C Wienkers. (2006) Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opinion on Drug Discovery 1:7, pages 677-691.
Read now
Read now
M. R. Shiran, N. J. Proctor, E. M. Howgate, K. Rowland-Yeo, G. T. Tucker & A. Rostami-Hodjegan. (2006) Prediction of metabolic drug clearance in humans: extrapolation allometric scaling. Xenobiotica 36:7, pages 567-580.
Read now
Read now
S. Inoue, E. M. Howgate, K. Rowland-Yeo, T. Shimada, H. Yamazaki, G. T. Tucker & A. Rostami-Hodjegan. (2006) Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36:6, pages 499-513.
Read now
Read now
Articles from other publishers (174)
Oroitz Sánchez-Aguinagalde, Eva Sanchez-Rexach, Yurena Polo, Aitor Larrañaga, Ainhoa Lejardi, Emilio Meaurio & Jose-Ramon Sarasua. (2024) Physicochemical Characterization and In Vitro Activity of Poly(ε-Caprolactone)/Mycophenolic Acid Amorphous Solid Dispersions. Polymers 16:8, pages 1088.
Crossref
Crossref
Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan & Neeraj Gupta. (2024) Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach. CPT: Pharmacometrics & Systems Pharmacology 13:4, pages 624-637.
Crossref
Crossref
Estefania Traver, Laura Rodríguez‐Pascau, Uwe Meya, Guillem Pina, Silvia Pascual, Sonia Poli, David Eckland, Jeroen van de Wetering, Alice Ke, Andreas Lindauer, Marc Martinell & Pilar Pizcueta. (2024)
Clinical pharmacokinetics of leriglitazone and a translational approach using
PBPK
modeling to guide the selection of the starting dose in children
. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Crossref
Nassim Djebli, Neil Parrott, Felix Jaminion, Amaury O'Jeanson, Elena Guerini & David Carlile. (2023)
Evaluation of the potential impact on pharmacokinetics of various cytochrome
P450
substrates of increasing
IL
‐6 levels following administration of the T‐cell bispecific engager glofitamab
. CPT: Pharmacometrics & Systems Pharmacology 13:3, pages 396-409.
Crossref
Crossref
Xian Pan, Khaled Abduljalil, Lisa M. Almond, Amita Pansari & Karen Rowland Yeo. (2023) Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example. CPT: Pharmacometrics & Systems Pharmacology 13:3, pages 386-395.
Crossref
Crossref
Udoamaka Ezuruike, Liam Curry, Oliver Hatley & Iain Gardner. (2024) Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: A case study with lansoprazole in Japanese subjects. British Journal of Clinical Pharmacology.
Crossref
Crossref
Agustos C. Ozbey, Stephen Fowler, Karen Leys, Pieter Annaert, Kenichi Umehara & Neil Parrott. (2024) Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives. Drug Metabolism and Disposition 52:1, pages 44-55.
Crossref
Crossref
Sandra Cvijić, Jelisaveta Ignjatović, Jelena Parojčić & Zorica Đurić. 2024. Computer-Aided Applications in Pharmaceutical Technology. Computer-Aided Applications in Pharmaceutical Technology
199
283
.
Paulo Paixão, Luís Gouveia, José Augusto Guimarães Morais & Nuno Silva. 2024. Concepts and Models for Drug Permeability Studies. Concepts and Models for Drug Permeability Studies
641
663
.
Marika A. de Hoop-Sommen, Joyce E. M. van der Heijden, Jolien J. M. Freriksen, Rick Greupink & Saskia N. de Wildt. (2023) Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: proof-of-concept. Frontiers in Pediatrics 11.
Crossref
Crossref
Ziping Yang, Nathalie Rioux, Ludwig Vincent, Hannah M. Jones, David Cha, Andrew Plummer, David Wilfret & Brian P. Kearney. (2023) A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir. CPT: Pharmacometrics & Systems Pharmacology 12:10, pages 1553-1564.
Crossref
Crossref
Karen Rowland Yeo, Oliver Hatley, Ben G. Small & Trevor N. Johnson. (2023) Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study. Pharmaceutics 15:7, pages 1922.
Crossref
Crossref
Xian Pan & Karen Rowland Yeo. (2023) Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. Clinical Pharmacology & Therapeutics 114:1, pages 182-191.
Crossref
Crossref
Mackenzie Bergagnini-Kolev, Katie Kane, Ian E. Templeton & Aidan K. Curran. (2023) Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data. The AAPS Journal 25:4.
Crossref
Crossref
Farzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, Debra Tompson, Jackie Bloomer, David B. Turner & Kunal S. Taskar. (2023) Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. CPT: Pharmacometrics & Systems Pharmacology 12:6, pages 808-820.
Crossref
Crossref
Karen Rowland Yeo & David Wesche. (2023) PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile. CPT: Pharmacometrics & Systems Pharmacology 12:5, pages 598-609.
Crossref
Crossref
Darcy J. Mulford, Diane Ramsden, Liming Zhang, Ingrid Michon, Eckhard Leifke, Neila Smith, Hannah M. Jones & Carmelo Scarpignato. (2023)
Tiered approach to evaluate the
CYP3A
victim and perpetrator drug–drug interaction potential for vonoprazan using
PBPK
modeling and clinical data to inform labeling
. CPT: Pharmacometrics & Systems Pharmacology 12:4, pages 532-544.
Crossref
Crossref
Kevin McNally, Craig Sams & George Loizou. (2023) Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data. Frontiers in Pharmacology 14.
Crossref
Crossref
Kevin McNally, Craig Sams, Alex Hogg & George Loizou. (2023) Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data. Frontiers in Pharmacology 14.
Crossref
Crossref
Kevin McNally & George Loizou. (2023) Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data. Frontiers in Pharmacology 14.
Crossref
Crossref
TIRTHA NANDI. (2023) IMPORTANCE OF SUFFICIENT TIME POINTS FOR EFFICIENT PHARMACOKINETIC (PK) COMPARTMENTAL MODELING. International Journal of Applied Pharmaceutics, pages 87-92.
Crossref
Crossref
Robert S. Foti, Joseph M. Roesner & Joshua T. Pearson. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
249
267
.
Dustin F. Kapraun, Mark Sfeir, Robert G Pearce, Sarah E Davidson-Fritz, Annie Lumen, André Dallmann, Richard S Judson & John F. Wambaugh. (2022) Evaluation of a rapid, generic human gestational dose model. Reproductive Toxicology 113, pages 172-188.
Crossref
Crossref
Olha Shuklinova, Przemysław Dorożyński, Piotr Kulinowski & Sebastian Polak. (2022) Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model. Pharmaceutics 14:7, pages 1514.
Crossref
Crossref
Doha Naga, Neil Parrott, Gerhard F. Ecker & Andrés Olivares-Morales. (2022) Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery. Molecular Pharmaceutics 19:7, pages 2203-2216.
Crossref
Crossref
Udoamaka Ezuruike, Mian Zhang, Amita Pansari, Mailys De Sousa Mendes, Xian Pan, Sibylle Neuhoff & Iain Gardner. (2022)
Guide to development of compound files for
PBPK
modeling in the Simcyp population‐based simulator
. CPT: Pharmacometrics & Systems Pharmacology 11:7, pages 805-821.
Crossref
Crossref
Dwaipayan Mukherjee, Manoj S. Chiney, Xi Shao, Tzuchi R. Ju, Mohamad Shebley & Patrick Marroum. (2022) Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. Biopharmaceutics & Drug Disposition 43:3, pages 98-107.
Crossref
Crossref
Adam S. Darwich, Oliver J. Hatley, Andrés Olivares‐Morales, Farzaneh Salem, Alison Margolskee & Amin Rostami‐Hodjegan. 2022. Oral Drug Delivery for Modified Release Formulations. Oral Drug Delivery for Modified Release Formulations
65
86
.
Karelle Ménochet, Hugues Chanteux, Jamie Henshall, Jean‐Marie Nicolas, Sara Wright, Judith van Asperen & Anna‐Lena Ungell. 2022. Oral Drug Delivery for Modified Release Formulations. Oral Drug Delivery for Modified Release Formulations
39
64
.
Elizabeth Hann, Karine Malagu, Andrew Stott & Huw Vater. 2022.
163
214
.
Malcolm Rowland. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
589
601
.
Kenneth H. Wills, Stephen J. Behan, Michael J. Nance, Jessica L. Dawson, Thomas M. Polasek, Ashley M. Hopkins, Madelé van Dyk & Andrew Rowland. (2021) Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure. Pharmaceutics 14:1, pages 47.
Crossref
Crossref
Sheri Smith, Michael Lyman, Bennett Ma, Donald Tweedie & Karsten Menzel. (2021) Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450. Drug Metabolism and Disposition 49:11, pages 995-1002.
Crossref
Crossref
Ryan H. Takahashi, William F. Forrest, Alexander D. Smith, Justine Badee, NaHong Qiu, Stephan Schmidt, Abby C. Collier, Neil Parrott & Stephen Fowler. (2021) Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes. Drug Metabolism and Disposition 49:9, pages 760-769.
Crossref
Crossref
Lei Sun, Zoe Barter, Lisa von Moltke & Karen Rowland Yeo. (2021) Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. CPT: Pharmacometrics & Systems Pharmacology 10:9, pages 1071-1080.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
567
577
.
Qiang Fu, Hannah M. Jones, Gang Sun & Sergei P. Atamas. (2021) A Physiologically Based Pharmacokinetic and Drug–Drug Interaction Model for the CB2 Agonist Lenabasum. European Journal of Drug Metabolism and Pharmacokinetics 46:4, pages 513-525.
Crossref
Crossref
Jayaprakasam Bolleddula, Alice Ke, Hua Yang & Chandra Prakash. (2021) PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. CPT: Pharmacometrics & Systems Pharmacology 10:6, pages 577-588.
Crossref
Crossref
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman & Ying C. Ou. (2021) Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. CPT: Pharmacometrics & Systems Pharmacology 10:5, pages 441-454.
Crossref
Crossref
Jaydeep Sinha, Stephen B. Duffull, Bruce Green & Hesham S. Al-Sallami. (2020) Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. Current Drug Metabolism 21:10, pages 746-750.
Crossref
Crossref
Hyun‐moon Back, Hwi‐yeol Yun, Sang Kyum Kim & Jae Kyoung Kim. (2020)
Beyond the Michaelis‐Menten: Accurate Prediction of
In Vivo
Hepatic Clearance for Drugs With Low
K
M
. Clinical and Translational Science 13:6, pages 1199-1207.
Crossref
Crossref
Chandra Prakash, Bin Fan, Alice Ke, Kha Le & Hua Yang. (2020) Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 86:5, pages 619-632.
Crossref
Crossref
Thomas J. Dennison, Julian C. Smith, Raj K.S. Badhan & Afzal R. Mohammed. (2020) Formulation and Bioequivalence Testing of Fixed-Dose Combination Orally Disintegrating Tablets for the Treatment of Tuberculosis in the Paediatric Population. Journal of Pharmaceutical Sciences 109:10, pages 3105-3113.
Crossref
Crossref
Yohei Kosugi & Natalie Hosea. (2020) Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. Molecular Pharmaceutics 17:7, pages 2299-2309.
Crossref
Crossref
Jaydeep Sinha, Stephen B. Duffull, Bruce Green & Hesham S. Al-Sallami. (2019) Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. Clinical Pharmacokinetics 59:4, pages 475-483.
Crossref
Crossref
Raju Prasad Sharma, Vikas Kumar, Marta Schuhmacher, Alexey Kolodkin & Hans V. Westerhoff. (2020) Development and evaluation of a harmonized whole body physiologically based pharmacokinetic (PBPK) model for flutamide in rats and its extrapolation to humans. Environmental Research 182, pages 108948.
Crossref
Crossref
Lei Sun, Lisa von Moltke & Karen Rowland Yeo. (2020) Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan. CPT: Pharmacometrics & Systems Pharmacology 9:2, pages 106-114.
Crossref
Crossref
Robert S. Jones, Justin Q. Ly & Jae H. Chang. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
555
594
.
Khaled Abo-EL-Sooud. 2020. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
879
885
.
Sylvia E. Escher, Hennicke Kamp, Susanne H. Bennekou, Annette Bitsch, Ciarán Fisher, Rabea Graepel, Jan G. Hengstler, Matthias Herzler, Derek Knight, Marcel Leist, Ulf Norinder, Gladys Ouédraogo, Manuel Pastor, Sharon Stuard, Andrew White, Barbara Zdrazil, Bob van de Water & Dinant Kroese. (2019) Towards grouping concepts based on new approach methodologies in chemical hazard assessment: the read-across approach of the EU-ToxRisk project. Archives of Toxicology 93:12, pages 3643-3667.
Crossref
Crossref
Kevin McNally, Craig Sams & George Loizou. (2019) Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data. Frontiers in Pharmacology 10.
Crossref
Crossref
Asha J Kapetas, Michael J Sorich, A David Rodrigues & Andrew Rowland. (2019) Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction. The AAPS Journal 21:5.
Crossref
Crossref
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter & Nidal Al‐Huniti. (2019)
Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite,
ACP
‐5862, Using a
Physiologically‐Based Pharmacokinetic
Modeling Approach
. CPT: Pharmacometrics & Systems Pharmacology 8:7, pages 489-499.
Crossref
Crossref
Felix Stader, Melissa A. Penny, Marco Siccardi & Catia Marzolini. (2019) A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab. CPT: Pharmacometrics & Systems Pharmacology 8:7, pages 444-459.
Crossref
Crossref
Alice Ban Ke & Mark A. Milad. (2019) Evaluation of Maternal Drug Exposure Following the Administration of Antenatal Corticosteroids During Late Pregnancy Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics 106:1, pages 164-173.
Crossref
Crossref
Krishna K. Machavaram, Chihiro Endo-Tsukude, Kimio Terao, Katherine L. Gill, Oliver J. Hatley, Iain Gardner, Neil Parrott & Patricia Sanwald Ducray. (2019) Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. The AAPS Journal 21:3.
Crossref
Crossref
Thomas M. Polasek, Craig R. Rayner, Richard W. Peck, Andrew Rowland, Holly Kimko & Amin Rostami‐Hodjegan. (2018) Toward Dynamic Prescribing Information: Codevelopment of Companion Model‐Informed Precision Dosing Tools in Drug Development. Clinical Pharmacology in Drug Development 8:4, pages 418-425.
Crossref
Crossref
Go-Wun Choi, Yong-Bok Lee & Hea-Young Cho. (2019) Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. Pharmaceutics 11:4, pages 168.
Crossref
Crossref
Adam S. Darwich, Howard J. Burt & Amin Rostami-Hodjegan. (2019) The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. European Journal of Pharmaceutical Sciences 131, pages 195-207.
Crossref
Crossref
Nuggehally R. Srinivas. (2019) Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug–Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy. American Journal of Therapeutics 26:1, pages e54-e65.
Crossref
Crossref
Neha Maharao, Jurgen Venitz & Phillip M. Gerk. (2019) Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability. Biopharmaceutics & Drug Disposition 40:1, pages 18-31.
Crossref
Crossref
Wen Lin, Jing-He Yan, Tycho Heimbach & Handan He. (2018) Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges. Current Pharmacology Reports 4:6, pages 491-501.
Crossref
Crossref
Jeffry Adiwidjaja, Alan V. Boddy & Andrew J. McLachlan. (2018) A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. CPT: Pharmacometrics & Systems Pharmacology 7:12, pages 798-808.
Crossref
Crossref
Manoranjenni Chetty, Trevor N. Johnson, Sebastian Polak, Farzaneh Salem, Kosuke Doki & Amin Rostami-Hodjegan. (2018) Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Advanced Drug Delivery Reviews 135, pages 85-96.
Crossref
Crossref
Qiang Zhang, Jin Li, Alistair Middleton, Sudin Bhattacharya & Rory B. Conolly. (2018) Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling. Frontiers in Public Health 6.
Crossref
Crossref
Wangda Zhou, Trevor N. Johnson, Khanh H. Bui, S.Y. Amy Cheung, Jianguo Li, Hongmei Xu, Nidal Al‐Huniti & Diansong Zhou. (2017) Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clinical Pharmacology & Therapeutics 104:1, pages 188-200.
Crossref
Crossref
Aiqun Li, Karen Yeo, Devin Welty & Haojing Rong. (2017) Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Pediatric Drugs 20:2, pages 181-194.
Crossref
Crossref
Huybrecht T’jollyn, An Vermeulen, Jan Van Bocxlaer & Pieter Colin. (2017) A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients. Clinical Pharmacokinetics 57:1, pages 59-69.
Crossref
Crossref
Khaled Abo-EL-Sooud. 2018. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
1
7
.
Khaled Abo-EL-Sooud. 2018. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
1
7
.
Jie Gao, Jie Wang, Na Gao, Xin Tian, Jun Zhou, Yan Fang, Hai-Feng Zhang, Qiang Wen, Lin-Jing Jia, Dan Zou & Hai-Ling Qiao. (2017) Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs. Bioscience Reports 37:6.
Crossref
Crossref
Shriram M. Pathak, Aaron Ruff, Edmund S. Kostewicz, Nikunjkumar Patel, David B. Turner & Masoud Jamei. (2017)
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated
in Vitro in Vivo
Extrapolation Perspective Using Ketoconazole as a Model Drug
. Molecular Pharmaceutics 14:12, pages 4305-4320.
Crossref
Crossref
Niloufar Marsousi, Jules A. Desmeules, Serge Rudaz & Youssef Daali. (2017) Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. Journal of Pharmaceutical Sciences 106:9, pages 2380-2391.
Crossref
Crossref
Caroline L. Ring, Robert G. Pearce, R. Woodrow Setzer, Barbara A. Wetmore & John F. Wambaugh. (2017) Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. Environment International 106, pages 105-118.
Crossref
Crossref
Rachel H. Rose, David B. Turner, Sibylle Neuhoff & Masoud Jamei. (2017) Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs. The AAPS Journal 19:4, pages 1205-1217.
Crossref
Crossref
Nuggehally R. Srinivas. (2017) Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir. American Journal of Therapeutics 24:4, pages e405-e418.
Crossref
Crossref
Bennett Ma, Roy Eisenhandler, Yuhsin Kuo, Paul Rearden, Ying Li, Peter J. Manley, Sheri Smith & Karsten Menzel. (2016) Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction. European Journal of Drug Metabolism and Pharmacokinetics 42:2, pages 319-326.
Crossref
Crossref
Bo Liu, H. Kim Crewe, Mahmut Ozdemir, Karen Rowland Yeo, Geoffrey Tucker & Amin Rostami‐Hodjegan. (2017) The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism. Biopharmaceutics & Drug Disposition 38:3, pages 260-270.
Crossref
Crossref
Jie Gao, Xin Tian, Jun Zhou, Ming-Zhu Cui, Hai-Feng Zhang, Na Gao, Qiang Wen & Hai-Ling Qiao. (2017) From Genotype to Phenotype: Cytochrome P450 2D6-Mediated Drug Clearance in Humans. Molecular Pharmaceutics 14:3, pages 649-657.
Crossref
Crossref
Angela Rowland, Arduino A. Mangoni, Ashley Hopkins, Michael J. Sorich & Andrew Rowland. (2016) Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil. Frontiers in Pharmacology 7.
Crossref
Crossref
Andrés Olivares-Morales, Avijit Ghosh, Leon Aarons & Amin Rostami-Hodjegan. (2016) Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin. The AAPS Journal 18:6, pages 1532-1549.
Crossref
Crossref
W Zhou, TN Johnson, H Xu, SYA Cheung, KH Bui, J Li, N Al‐Huniti & D Zhou. (2016) Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children. CPT: Pharmacometrics & Systems Pharmacology 5:9, pages 475-483.
Crossref
Crossref
Susanne Johansson, Boel Löfberg, Maria Aunes, Helen Lunde, Lars Frison, Nils Edvardsson & Marie Cullberg. (2016) In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. Clinical Pharmacology in Drug Development 5:5, pages 364-373.
Crossref
Crossref
H. J. Burt, A. E. Riedmaier, M. D. Harwood, H. K. Crewe, K. L. Gill & S. Neuhoff. (2016) Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis. Drug Metabolism and Disposition 44:10, pages 1550-1561.
Crossref
Crossref
Kenta Haraya, Motohiro Kato, Koji Chiba & Yuichi Sugiyama. (2016) Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers. Drug Metabolism and Pharmacokinetics 31:4, pages 276-284.
Crossref
Crossref
Nuggehally R. Srinivas. (2016) Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clinical Neuropharmacology 39:4, pages 169-177.
Crossref
Crossref
Sheng Feng, Jun Shi, Neil Parrott, Pei Hu, Cornelia Weber, Meret Martin-Facklam, Tomohisa Saito & Richard Peck. (2015) Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. Clinical Pharmacokinetics 55:7, pages 823-832.
Crossref
Crossref
L. R. A. Rougee, Z. Riches, J. M. Berman & A. C. Collier. (2016) The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1). Drug Metabolism and Disposition 44:7, pages 967-974.
Crossref
Crossref
Jie Gao, Jun Zhou, Xiao-Pei He, Yun-Fei Zhang, Na Gao, Xin Tian, Yan Fang, Qiang Wen, Lin-Jing Jia, Han Jin & Hai-Ling Qiao. (2016)
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma
in vitro
and
in vivo
: a bottom-up approach
. Oncotarget 7:19, pages 28612-28623.
Crossref
Crossref
Nuggehally R. Srinivas. (2016) Prediction of area under the concentration–time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir–ritonavir therapy. American Journal of Health-System Pharmacy 73:6, pages 376-385.
Crossref
Crossref
Nuggehally R. Srinivas & Muzeeb Syed. (2016) Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of C trough- over C max-Derived Linear Regression Models. Drugs in R&D 16:1, pages 69-79.
Crossref
Crossref
Angela Colbers, Rick Greupink, Carlijn Litjens, David Burger & Frans G. M. Russel. (2015) Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. Clinical Pharmacokinetics 55:3, pages 381-396.
Crossref
Crossref
Hong-yun Wang, Xia Chen, Ji Jiang, Jun Shi & Pei Hu. (2015) Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacologica Sinica 37:2, pages 276-284.
Crossref
Crossref
Paulo Paixão, Luís Gouveia, José Augusto Guimarães Morais & Nuno Silva. 2016. Concepts and Models for Drug Permeability Studies. Concepts and Models for Drug Permeability Studies
357
371
.
Haifeng Zhang, Na Gao, Xin Tian, Tingting Liu, Yan Fang, Jun Zhou, Qiang Wen, Binbin Xu, Bing Qi, Jie Gao, Hongmeng Li, Linjing Jia & Hailing Qiao. (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Scientific Reports 5:1.
Crossref
Crossref
Thierry Wendling, Swati Dumitras, Kayode Ogungbenro & Leon Aarons. (2015) Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 42:6, pages 639-657.
Crossref
Crossref
Nuggehally R. Srinivas. (2015) Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharmaceutics & Drug Disposition 36:9, pages 575-586.
Crossref
Crossref
Lois J. Haupt, Faraz Kazmi, Brian W. Ogilvie, David B. Buckley, Brian D. Smith, Sarah Leatherman, Brandy Paris, Oliver Parkinson & Andrew Parkinson. (2015)
The Reliability of Estimating
K
i
Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC
50
Values: A Retrospective Analysis of 343 Experiments
. Drug Metabolism and Disposition 43:11, pages 1744-1750.
Crossref
Crossref
Alexander V. LyubimovYuan Chen, Jialin Mao & Adrian J. Fretland. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
26
.
Boyd Steere, Jessica A. Roseberry Baker, Stephen D. Hall & Yingying Guo. (2015) Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model. Drug Metabolism and Disposition 43:6, pages 870-883.
Crossref
Crossref
Kevin McNally, Richard Cotton, Alex Hogg & George Loizou. (2015) Reprint of PopGen: A virtual human population generator. Toxicology 332, pages 77-93.
Crossref
Crossref
Manoranjenni Chetty, Rachel H. Rose, Khaled Abduljalil, Nikunjkumar Patel, Gaohua Lu, Theresa Cain, Masoud Jamei & Amin Rostami-Hodjegan. (2014) Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Frontiers in Pharmacology 5.
Crossref
Crossref
Barbara A. Wetmore, Brittany Allen, Harvey J. ClewellIIIIII, Timothy Parker, John F. Wambaugh, Lisa M. Almond, Mark A. Sochaski & Russell S. Thomas. (2014) Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing. Toxicological Sciences 142:1, pages 210-224.
Crossref
Crossref
Khaled Abduljalil, Theresa Cain, Helen Humphries & Amin Rostami-Hodjegan. (2014) Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. Drug Metabolism and Disposition 42:9, pages 1478-1484.
Crossref
Crossref
Tetsuya Mitsui, Takayuki Nemoto, Taiji Miyake, Shunsuke Nagao, Kotaro Ogawa, Motohiro Kato, Masaki Ishigai & Hideyuki Yamada. (2014) A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes. Drug Metabolism and Disposition 42:9, pages 1540-1547.
Crossref
Crossref
Trevor N. Johnson, Diansong Zhou & Khanh H. Bui. (2014) Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharmaceutics & Drug Disposition 35:6, pages 341-352.
Crossref
Crossref
Franco Lombardo, R. Scott Obach, Manthena V. Varma, Rowan Stringer & Giuliano Berellini. (2014) Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models. Journal of Medicinal Chemistry 57:10, pages 4397-4405.
Crossref
Crossref
Kevin McNally, Richard Cotton, Alex Hogg & George Loizou. (2014) PopGen: A virtual human population generator. Toxicology 315, pages 70-85.
Crossref
Crossref
Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li & Zeruesenay Desta. (2013) CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition 41:12, pages 2004-2011.
Crossref
Crossref
Zoe E. Barter, Geoffrey T. Tucker & Karen Rowland-Yeo. (2013) Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 52:12, pages 1085-1100.
Crossref
Crossref
Jian Wang, Sumei Xia, Weifang Xue, Dawei Wang, Yang Sai, Li Liu & Xiaodong Liu. (2013) A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. European Journal of Pharmaceutical Sciences 50:3-4, pages 290-302.
Crossref
Crossref
Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner & Amin Rostami‐Hodjegan. (2013) Application of permeability‐limited physiologically-based pharmacokinetic models: Part II-prediction of p‐glycoprotein mediated drug–drug interactions with digoxin. Journal of Pharmaceutical Sciences 102:9, pages 3161-3173.
Crossref
Crossref
Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner & Amin Rostami-Hodjegan. (2013) Application of permeability-limited physiologically-based pharmacokinetic models: Part I–digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. Journal of Pharmaceutical Sciences 102:9, pages 3145-3160.
Crossref
Crossref
Rick Greupink, Marieke Schreurs, Marina S. Benne, Maarten T. Huisman & Frans G.M. Russel. (2013) Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug–drug-interactions. European Journal of Pharmaceutical Sciences 49:5, pages 819-828.
Crossref
Crossref
Neil Parrott, Dominik Hainzl, Daniela Alberati, Carsten Hofmann, Richard Robson, Bruno Boutouyrie & Meret Martin-Facklam. (2013) Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics 52:8, pages 673-683.
Crossref
Crossref
Patricio Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes Georg Bode, Jennifer Bolleyn, Christoph Borner, Jan Böttger, Albert Braeuning, Robert A. Budinsky, Britta Burkhardt, Neil R. Cameron, Giovanni Camussi, Chong-Su Cho, Yun-Jaie Choi, J. Craig Rowlands, Uta Dahmen, Georg Damm, Olaf Dirsch, María Teresa Donato, Jian Dong, Steven Dooley, Dirk Drasdo, Rowena Eakins, Karine Sá Ferreira, Valentina Fonsato, Joanna Fraczek, Rolf Gebhardt, Andrew Gibson, Matthias Glanemann, Chris E. P. Goldring, María José Gómez-Lechón, Geny M. M. Groothuis, Lena Gustavsson, Christelle Guyot, David Hallifax, Seddik Hammad, Adam Hayward, Dieter Häussinger, Claus Hellerbrand, Philip Hewitt, Stefan Hoehme, Hermann-Georg Holzhütter, J. Brian Houston, Jens Hrach, Kiyomi Ito, Hartmut Jaeschke, Verena Keitel, Jens M. Kelm, B. Kevin Park, Claus Kordes, Gerd A. Kullak-Ublick, Edward L. LeCluyse, Peng Lu, Jennifer Luebke-Wheeler, Anna Lutz, Daniel J. Maltman, Madlen Matz-Soja, Patrick McMullen, Irmgard Merfort, Simon Messner, Christoph Meyer, Jessica Mwinyi, Dean J. Naisbitt, Andreas K. Nussler, Peter Olinga, Francesco Pampaloni, Jingbo Pi, Linda Pluta, Stefan A. Przyborski, Anup Ramachandran, Vera Rogiers, Cliff Rowe, Celine Schelcher, Kathrin Schmich, Michael Schwarz, Bijay Singh, Ernst H. K. Stelzer, Bruno Stieger, Regina Stöber, Yuichi Sugiyama, Ciro Tetta, Wolfgang E. Thasler, Tamara Vanhaecke, Mathieu Vinken, Thomas S. Weiss, Agata Widera, Courtney G. Woods, Jinghai James Xu, Kathy M. Yarborough & Jan G. Hengstler. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 87:8, pages 1315-1530.
Crossref
Crossref
AS Darwich, D Pade, K Rowland‐Yeo, M Jamei, A Åsberg, H Christensen, DM Ashcroft & A Rostami‐Hodjegan. (2013)
Evaluation of an
In Silico
PBPK Post‐Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
. CPT: Pharmacometrics & Systems Pharmacology 2:6, pages 1-9.
Crossref
Crossref
Karen Rowland Yeo, Jane R. Kenny & Amin Rostami-Hodjegan. (2013) Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. European Journal of Clinical Pharmacology 69:6, pages 1311-1320.
Crossref
Crossref
Thomas M. Polasek, Farhaan Patel, Berit P. Jensen, Michael J. Sorich, Michael D. Wiese & Matthew P. Doogue. (2013) Predicted metabolic drug clearance with increasing adult age. British Journal of Clinical Pharmacology 75:4, pages 1019-1028.
Crossref
Crossref
Sravanthi Cheeti, Nageshwar R. Budha, Sharmila Rajan, Mark J. Dresser & Jin Y. Jin. (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharmaceutics & Drug Disposition 34:3, pages 141-154.
Crossref
Crossref
J. Jornil, T.S. Nielsen, I. Rosendal, J. Ahlner, A.L. Zackrisson, L.W.T. Boel & B. Brock. (2013) A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Science International 226:1-3, pages e26-e31.
Crossref
Crossref
Sandra Grbic, Jelena Parojcic & Zorica Djuric. 2013. Computer-Aided Applications in Pharmaceutical Technology. Computer-Aided Applications in Pharmaceutical Technology
177
232
.
Anne M. Filppula, Mikko Neuvonen, Jouko Laitila, Pertti J. Neuvonen & Janne T. Backman. (2013) Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. Drug Metabolism and Disposition 41:1, pages 50-59.
Crossref
Crossref
Helena Anna Thörn, Erik Sjögren, Paul Alfred Dickinson & Hans Lennernäs. (2012)
Binding Processes Determine the Stereoselective Intestinal and Hepatic Extraction of Verapamil
in Vivo
. Molecular Pharmaceutics 9:11, pages 3034-3045.
Crossref
Crossref
SK Quinney, AN Mohamed, MF Hebert, DM Haas, S Clark, JG Umans, SN Caritis & L Li. (2012) A Semi‐Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology 1:9, pages 1-9.
Crossref
Crossref
Giuliano Berellini, Nigel J. Waters & Franco Lombardo. (2012) In silico Prediction of Total Human Plasma Clearance. Journal of Chemical Information and Modeling 52:8, pages 2069-2078.
Crossref
Crossref
Adam S Darwich, Devendra Pade, Basil J Ammori, Masoud Jamei, Darren M Ashcroft & Amin Rostami-Hodjegan. (2012) A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. Journal of Pharmacy and Pharmacology 64:7, pages 1008-1024.
Crossref
Crossref
David R. Plowchalk & Karen Rowland Yeo. (2012) Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. European Journal of Clinical Pharmacology 68:6, pages 951-960.
Crossref
Crossref
Alexander V. LyubimovFrédéric Y. Bois & Masoud Jamei. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
. 2012. Pharmacokinetics and Metabolism in Drug Design. Pharmacokinetics and Metabolism in Drug Design
209
227
.
Michael Zientek & Deepak Dalvie. (2012) Use of a Multistaged Time-Dependent Inhibition Assay to Assess the Impact of Intestinal Metabolism on Drug-Drug Interaction Potential. Drug Metabolism and Disposition 40:3, pages 467-473.
Crossref
Crossref
Yuan Chen, Jin Y. Jin, Sophie Mukadam, Vikram Malhi & Jane R. Kenny. (2012) Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharmaceutics & Drug Disposition 33:2, pages 85-98.
Crossref
Crossref
Christopher L. Shaffer, Renato J. Scialis, Haojing Rong & R. Scott Obach. (2012) Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism‐based adverse events. Biopharmaceutics & Drug Disposition 33:2, pages 72-84.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
407
421
.
Kevin McNally, Richard Cotton, John Cocker, Kate Jones, Mike Bartels, David Rick, Paul Price & George Loizou. (2012)
Reconstruction of Exposure to
m
-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation
. Journal of Toxicology 2012, pages 1-18.
Crossref
Crossref
Malcolm Rowland & Robert L. Dedrick. 2012. Principles of Clinical Pharmacology. Principles of Clinical Pharmacology
531
540
.
Elaina M. Kenyon. 2012. Computational Toxicology. Computational Toxicology
501
520
.
Cyrus Ghobadi, Trevor N. Johnson, Mohsen Aarabi, Lisa M. Almond, Aurel Constant Allabi, Karen Rowland-Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. Clinical Pharmacokinetics 50:12, pages 809-822.
Crossref
Crossref
Hisakazu Ohtani, Zoe Barter, Tsuyoshi Minematsu, Masatoshi Makuuchi, Yasufumi Sawada & Amin Rostami‐Hodjegan. (2011) Bottom‐up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics & Drug Disposition 32:9, pages 498-506.
Crossref
Crossref
Jakob Jornil, Klaus Gjervig Jensen, Frank Larsen & Kristian Linnet. (2011) Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. European Journal of Pharmaceutical Sciences 44:3, pages 265-272.
Crossref
Crossref
Jiansong Yang. 2011. Systems Biology in Drug Discovery and Development. Systems Biology in Drug Discovery and Development
59
92
.
H. K. Crewe, Z. E. Barter, K. Rowland Yeo & A. Rostami‐Hodjegan. (2011) Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors. Biopharmaceutics & Drug Disposition 32:6, pages 303-318.
Crossref
Crossref
Nitsupa Wattanachai, Thomas M. Polasek, Tahlia M. Heath, Verawan Uchaipichat, Wongwiwat Tassaneeyakul, Wichittra Tassaneeyakul & John O. Miners. (2011) In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. European Journal of Clinical Pharmacology 67:8, pages 815-824.
Crossref
Crossref
Hannah M. Jones, Iain B. Gardner, Wendy T. Collard, Phil J. Stanley, Penny Oxley, Natilie A. Hosea, David Plowchalk, Steve Gernhardt, Jing Lin, Maurice Dickins, S. Ravi Rahavendran, Barry C. Jones, Kenny J. Watson, Henry Pertinez, Vikas Kumar & Susan Cole. (2011) Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 50:5, pages 331-347.
Crossref
Crossref
Yuan Chen, Liling Liu, Khanh Nguyen & Adrian J. Fretland. (2011) Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450. Drug Metabolism and Disposition 39:3, pages 373-382.
Crossref
Crossref
Paola Motta, Nicoletta Pons, Sabrina Pagliarusco, Mario Pellegatti & Fiorenza Bonomo. (2011) Casopitant: In Vitro Data and SimCyp Simulation to Predict In Vivo Metabolic Interactions Involving Cytochrome P450 3A4. Drug Metabolism and Disposition 39:3, pages 363-372.
Crossref
Crossref
Trevor N. Johnson & Amin Rostami‐Hodjegan. (2011) Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatric Anesthesia 21:3, pages 291-301.
Crossref
Crossref
Malcolm RowlandCarl Peck & Geoffrey Tucker. (2011) Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annual Review of Pharmacology and Toxicology 51:1, pages 45-73.
Crossref
Crossref
Yan-liu Lu, Yu-qi He, Miao Wang, Li Zhang, Li Yang, Zheng-tao Wang & Guang Ji. (2010) Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals. Acta Pharmacologica Sinica 31:12, pages 1635-1642.
Crossref
Crossref
Frédéric Y. Bois, Masoud Jamei & Harvey J. Clewell. (2010) PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:3, pages 256-267.
Crossref
Crossref
Andrew Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffini N. Hensley & Greg J. Loewen. 2010. Biotransformation and Metabolite Elucidation of Xenobiotics. Biotransformation and Metabolite Elucidation of Xenobiotics
1
77
.
Z. E. Barter, H. F. Perrett, K. Rowland Yeo, D. Allorge, M. S. Lennard & A. Rostami‐Hodjegan. (2010) Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharmaceutics & Drug Disposition 31:8-9, pages 516-532.
Crossref
Crossref
Melvin J. Yu. (2010) Predicting Total Clearance in Humans from Chemical Structure. Journal of Chemical Information and Modeling 50:7, pages 1284-1295.
Crossref
Crossref
Nathalie Perdaems, Helene Blasco, Cedric Vinson, Marylore Chenel, Sarah Whalley, Fanny Cazade & François Bouzom. (2010) Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling. Clinical Pharmacokinetics 49:4, pages 239-258.
Crossref
Crossref
Trevor N. Johnson, Koen Boussery, Karen Rowland-Yeo, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2010) A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics 49:3, pages 189-206.
Crossref
Crossref
Karen Rowland Yeo, Masoud Jamei, Jiansong Yang, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2010) Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam. European Journal of Pharmaceutical Sciences 39:5, pages 298-309.
Crossref
Crossref
Motohiro Kato, Koji Chiba, Takashi Ito, Toshiko Koue & Yuichi Sugiyama. (2010) Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans. Drug Metabolism and Pharmacokinetics 25:4, pages 367-378.
Crossref
Crossref
K. Sandy Pang, Raimund M. Peter & A. David Rodrigues. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
701
722
.
Frederique Fenneteau, Patrick Poulin & Fahima Nekka. (2010) Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates. Journal of Pharmaceutical Sciences 99:1, pages 486-514.
Crossref
Crossref
Thomas M. Polasek, Sebastian Polak, Matthew P. Doogue, Amin Rostami-Hodjegan & John O. Miners. (2009) Assessment of inter-individual variability in predicted phenytoin clearance. European Journal of Clinical Pharmacology 65:12, pages 1203-1210.
Crossref
Crossref
Yu-qi He, Li Yang, Yong Liu, Jiang-wei Zhang, Jun Tang, Juan Su, Yuan-yuan Li, Yan-liu Lu, Chang-hong Wang, Ling Yang & Zheng-tao Wang. (2009) Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry. Acta Pharmacologica Sinica 30:10, pages 1462-1470.
Crossref
Crossref
Trevor N. Johnson, Thomas Kerbusch, Barry Jones, Geoffrey T. Tucker, Amin Rostami‐Hodjegan & Peter A. Milligan. (2009)
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using
in vitro
data as an aid to assess study power
. Pharmaceutical Statistics 8:3, pages 186-202.
Crossref
Crossref
Masoud Jamei, David Turner, Jiansong Yang, Sibylle Neuhoff, Sebastian Polak, Amin Rostami-Hodjegan & Geoffrey Tucker. (2009) Population-Based Mechanistic Prediction of Oral Drug Absorption. The AAPS Journal 11:2, pages 225-237.
Crossref
Crossref
Raj Badhan, Jeffrey Penny, Aleksandra Galetin & J. Brian Houston. (2009) Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. Journal of Pharmaceutical Sciences 98:6, pages 2180-2197.
Crossref
Crossref
Rowan A. Stringer, Claire Strain-Damerell, Paul Nicklin & J. Brian Houston. (2009) Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions. Drug Metabolism and Disposition 37:5, pages 1025-1034.
Crossref
Crossref
Kenneth H. Grime, James Bird, Douglas Ferguson & Robert J. Riley. (2009) Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36:2-3, pages 175-191.
Crossref
Crossref
Stephen Fowler & Hongjian Zhang. (2008) In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions. The AAPS Journal 10:2, pages 410-424.
Crossref
Crossref
Kuresh A. Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Michelle Griffiths, Amanda Darekar, Ruth Hyland, Odette Fahmi, Susan Hurst, David R. Plowchalk, Jack Cook, Feng Guo & R. Scott Obach. (2008)
Application of CYP3A4
in vitro
data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction
. British Journal of Clinical Pharmacology 65:5, pages 680-692.
Crossref
Crossref
Uwe Fuhr. (2008) Improvement in the handling of drug–drug interactions. European Journal of Clinical Pharmacology 64:2, pages 167-171.
Crossref
Crossref
Ashok Rakhit, Michael P. Pantze, Scott Fettner, Hannah M. Jones, Jean-Eric Charoin, Myriam Riek, Bert L. Lum & Marta Hamilton. (2007) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology 64:1, pages 31-41.
Crossref
Crossref
Gemma L. Dickinson & Amin Rostami‐Hodjegan. 2007. Biosimulation in Drug Development. Biosimulation in Drug Development
425
446
.
Gemma L. Dickinson, Martin S. Lennard, Geoffrey T. Tucker & Amin Rostami‐Hodjegan. (2007)
The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –
CYP2C9
and warfarin as an example
. British Journal of Clinical Pharmacology 64:1, pages 14-26.
Crossref
Crossref
Gemma L. Dickinson, Saeed Rezaee, Nicholas J. Proctor, Martin S. Lennard, Geoffrey T. Tucker & Amin Rostami‐Hodjegan. (2013) Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application. The Journal of Clinical Pharmacology 47:2, pages 175-186.
Crossref
Crossref
Amin Rostami-Hodjegan & Geoffrey T. Tucker. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery 6:2, pages 140-148.
Crossref
Crossref